KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Equity Income (2019 - 2025)

Historic Equity Income for Resmed (RMD) over the last 8 years, with Q4 2025 value amounting to $1.5 million.

  • Resmed's Equity Income rose 20528.14% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$12.9 million, marking a year-over-year decrease of 53298.87%. This contributed to the annual value of -$10.3 million for FY2025, which is 15461.06% down from last year.
  • As of Q4 2025, Resmed's Equity Income stood at $1.5 million, which was up 20528.14% from -$6.2 million recorded in Q3 2025.
  • Resmed's 5-year Equity Income high stood at $24.4 million for Q2 2021, and its period low was -$15.5 million during Q2 2024.
  • Its 5-year average for Equity Income is $49950.0, with a median of -$2.2 million in 2023.
  • In the last 5 years, Resmed's Equity Income soared by 50846.72% in 2021 and then tumbled by 87689.39% in 2024.
  • Resmed's Equity Income (Quarter) stood at -$4.4 million in 2021, then skyrocketed by 290.01% to $8.4 million in 2022, then tumbled by 122.56% to -$1.9 million in 2023, then rose by 23.78% to -$1.4 million in 2024, then soared by 205.28% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q4 2025, -$6.2 million for Q3 2025, and -$2.5 million during Q2 2025.